Employment Agreement



 Exhibit 10.13 
 EMPLOYMENT AGREEMENT 
 AGREEMENT (the “Agreement”), dated as of May 1, 2009, by
and between Chelsea Therapeutics International, Ltd., a Delaware corporation with principal executive offices at 3530 Toringdon Way, Unit 200, Charlotte, North Carolina 28277 (the “Company”), and DR. SIMON PEDDER, residing at 1347
Shinnecock Lane, Fort Mill, South Carolina 29707 (the “Executive”). 
 W I T N E S S E T H: 
 WHEREAS, the Company desires to continue to employ the Executive as President and Chief Executive Officer of the Company, and the Executive desires to
continue to serve the Company in those capacities, upon the terms and subject to the conditions contained in this Agreement; 
 NOW,
THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties hereto hereby agree as follows: 
 1.
Employment. 
 (a) Services. The Executive will be employed by the Company as its President and Chief Executive Officer. The
Executive will report to the Board of Directors of the Company (the “Board”) and shall perform such duties as are consistent with his position as President and Chief Executive Officer (the “Services”). The Executive
agrees to perform such duties faithfully, to devote substantially all of his working time, attention and energies to the business of the Company, and while he remains employed, not to engage in any other business activity that is in conflict with
his duties and obligations to the Company. 
 (b) Acceptance. Executive hereby accepts such employment and agrees to render the
Services. 
 2. Term. 
 Subject to earlier termination in accordance with Section 9 of this Agreement, the Executive’s employment under this Agreement shall commence as of May 1, 2009 or such other date as may be agreed to by the Parties (the
“Effective Date”) and shall continue for a term of three (3) years (the “Term”). The Term may be extended for additional one (1) year periods upon the mutual written agreement of the Executive and the
Board. In the event that either party determines not to extend the Term, such party will provide the other party with at least 90 days prior written notice. 
 3. Best Efforts; Place of Performance. 
 (a) The Executive shall devote substantially all of his
business time, attention and energies to the business and affairs of the Company and shall use his best efforts to advance the best interests of the Company and shall not during the Term be actively engaged in any other business activity, whether or
not such business activity is pursued for gain, profit or other 








 
pecuniary advantage, that will interfere with the performance by the Executive of his duties hereunder or the Executive’s availability to perform such
duties or that will adversely affect, or negatively reflect upon, the Company. 
 (b) The duties to be performed by the Executive hereunder
shall be performed in North Carolina or at such place as may be agreed upon by the Executive and the Board. 
 4. Directorship. The
Company shall use its best efforts to cause the Executive to be elected as a member of its Board throughout the Term and shall include him in the management slate for election as a director at every stockholders meeting during the Term at which his
term as a director would otherwise expire. The Executive agrees to accept election, and to serve during the Term, as director of the Company, without any compensation therefor other than as specified in this Agreement. 
 5. Compensation. As full compensation for the performance by the Executive of his duties under this Agreement, the Company shall pay the Executive
as follows: 
 (a) Base Salary. The Company shall pay Executive a salary (the “Base Salary”) equal to Four Hundred
Fourty-Seven Thousand, One Hundred and Sixty Dollars ($447,160) per year. Payment shall be made in accordance with the Company’s normal payroll practices. The amount of increase reflected in this Base Salary as compared to the salary rate being
paid immediately prior to the Term shall be paid retroactively to January 1, 2009. 
 (b) Incentive Bonus. The Executive shall
participate in the Company’s annual incentive bonus program for executive officers. Under the incentive bonus program, the Executive shall be entitled to an additional annual bonus (the “Incentive Bonus”) in an amount targeted
at 45% of his Base Salary if the fiscal year corporate goals set by the Board or Compensation Committee and communicated to the Executive are achieved at 100%. The Board or Compensation Committee has the authority to increase the Incentive Bonus to
up to 67.5% of the Executive’s Base Salary if the fiscal year corporate goals are exceeded or based on exemplary performance during the fiscal year by Executive. The Incentive Bonus shall be payable either as a lump-sum payment or in
installments as determined by the Board or Compensation Committee in its sole discretion. In either case, the entire amount must be paid no later than the March 15 of the calendar year immediately following the calendar year in which the fiscal
year ends. The Board or Compensation Committee shall annually review the Incentive Bonus to determine whether an increase in the amount thereof is warranted. No guaranteed bonus or other bonus related compensation shall be paid for calendar year
2009 or subsequent years under this Agreement or any prior agreement. 
 (c) Option Grants and Equity Awards. 
 Executive shall be entitled to participate in any stock option or equity compensation plan or program maintained by the Company and shall receive grants
and awards under such plans or programs commensurate with his position as President and Chief Executive Officer. The Company represents and warrants to the Executive that, as of April 1, 2009, there are 37,926,968 shares of Common Stock (as
hereinafter defined) outstanding on a fully-diluted basis. (For purposes hereof, the “Common Stock” means the Company’s common stock, par value $0.0001 








 
per share). Without limiting the generality of the first sentence of this Section 5(d), as additional consideration for the services to be rendered by
the Executive pursuant to this Agreement, effective as of the Effective Date, the Company shall grant the Executive an option to purchase that number of shares of Common Stock necessary to ensure that, immediately after such grant, the
Executive’s total ownership of the Company, including outstanding Common Stock and options to acquire Common Stock, equals 4.75% of the number of shares of Common Stock outstanding on a fully-diluted basis as of April 1, 2009. Such stock
options will be granted under and pursuant to the terms of the Company’s 2004 Stock Plan and will be granted to the extent possible as incentive stock options under the Internal Revenue Code of 1986, as amended (the “Code”).
The options will vest in four equal annual installments commencing on the first anniversary of the Effective Date and on each of the next three anniversaries thereafter provided that Executive remains in the employ of the Company on such
anniversary. Vesting may occur sooner in accordance with Section 10 of this Agreement. 
 (d) Withholding. The Company shall
withhold all applicable federal, state and local taxes and social security and such other amounts as may be required by law or authorized by Executive from all amounts payable to the Executive under this Section 5. 
 (e) Expenses. The Company shall reimburse the Executive for all normal, usual and necessary business expenses incurred by the Executive in
furtherance of the business and affairs of the Company, including reasonable travel and entertainment, upon timely receipt by the Company of appropriate vouchers or other proof of the Executive’s expenditures and otherwise in accordance with
any expense reimbursement policy as may from time to time be adopted by the Company. 
 (f) Other Benefits. The Executive shall be
entitled to all rights and benefits for which he shall be eligible under any benefit or other plans (including, without limitation, dental, medical, medical reimbursement and hospital plans, pension plans, employee stock purchase plans, profit
sharing plans, bonus plans and other so-called “fringe” benefits) as the Company shall make available to its senior executives from time to time. In addition, the Company shall reimburse the Executive for any calendar year for his
reasonable medical licensing fees and other professional dues incurred during the Term provided that the Executive remains in the employ of the Company. The Company shall reimburse Executive for such fees and dues promptly upon receipt of
appropriate proof of the Executive’s expenditures. To receive reimbursement, Executive must provide proof of the expenditures to the Company within 45 days of the date on which the expense was incurred. The Company’s reimbursement must be
paid not later than 30 days after receipt of proof of the expenditures. The amount of such fees and dues eligible for reimbursement during a calendar year shall not affect the amount of such fees and dues eligible for reimbursement during any other
calendar year. The Executive’s right to reimbursement of medical licensing fees and other professional dues shall not be subject to liquidation or exchange for another benefit. 
 (g) Vacation. The Executive shall, during the Term, be entitled to a vacation of four (4) weeks per annum, in addition to holidays observed
by the Company. The Executive shall not be entitled to carry any vacation forward to the next year of employment and shall not receive any compensation for unused vacation days upon termination of employment or otherwise. 







 6. Confidential Information and Inventions. 
 (a) The Executive recognizes and acknowledges that in the course of his duties he is likely to receive confidential or proprietary information owned by
the Company, its affiliates or third parties with whom the Company or any such affiliates has an obligation of confidentiality. Accordingly, during and after the Term, the Executive agrees to keep confidential and not disclose or make accessible to
any other person or use for any other purpose other than in connection with the fulfillment of his duties under this Agreement, any Confidential and Proprietary Information (as defined below) owned by, or received by or on behalf of, the Company or
any of its affiliates. “Confidential and Proprietary Information” shall include, but shall not be limited to, confidential or proprietary scientific or technical information, data, formulas and related concepts, business plans (both
current and under development), client lists, promotion and marketing programs, trade secrets, or any other confidential or proprietary business information relating to development programs, costs, revenues, marketing, investments, sales activities,
promotions, credit and financial data, manufacturing processes, financing methods, non-public personnel information, plans or the business and affairs of the Company or of any affiliate or client of the Company. The Executive expressly acknowledges
the trade secret status of the Confidential and Proprietary Information and that the Confidential and Proprietary Information constitutes a protectable business interest of the Company. The Executive agrees: (i) not to use any such Confidential
and Proprietary Information for himself or others; and (ii) not to take any Company material or reproductions (including but not limited to writings, correspondence, notes, drafts, records, invoices, technical and business policies, computer
programs or disks) thereof from the Company’s offices at any time during his employment by the Company, except as required in the execution of the Executive’s duties to the Company. The Executive agrees to return immediately all Company
material and reproductions (including but not limited, to writings, correspondence, notes, drafts, records, invoices, technical and business policies, computer programs or disks) thereof in his possession to the Company upon request and in any event
immediately upon termination of employment. 
 (b) Except with prior written authorization by the Company, the Executive agrees not to
disclose or publish any of the Confidential and Proprietary Information, or any confidential, scientific, technical or business information of any other party to whom the Company or any of its affiliates owes an obligation of confidence, at any time
during or after his employment with the Company. 
 (c) The Executive agrees that all inventions, discoveries, improvements and patentable or
copyrightable works (“Inventions”) initiated, conceived or made by him, either alone or in conjunction with others, during the Term shall be the sole property of the Company to the maximum extent permitted by applicable law and, to
the extent permitted by law, shall be “works made for hire” as that term is defined in the United States Copyright Act (17 U.S.C.A., Section 101). The Company shall be the sole owner of all patents, copyrights, trade secret rights,
and other intellectual property or other rights in connection therewith. The Executive hereby assigns to the Company all right, title and interest he may have or acquire in all such Inventions; provided, however, that the Board may in its sole
discretion agree to waive the Company’s rights pursuant to this Section 6(c) with respect to any Invention that is not directly or indirectly related to the Company’s business. The Executive further agrees to assist the Company in
every proper way (but at the Company’s expense) to obtain and from time to time enforce patents, copyrights 








 
or other rights on such Inventions in any and all countries, and to that end the Executive will execute all documents necessary: 
 (i) to apply for, obtain and vest in the name of the Company alone (unless the Company otherwise directs) letters patent, copyrights or other analogous
protection in any country throughout the world and when so obtained or vested to renew and restore the same; and 
 (ii) to defend any
opposition proceedings in respect of such applications and any opposition proceedings or petitions or applications for revocation of such letters patent, copyright or other analogous protection. 
 (d) The Executive acknowledges that while performing the services under this Agreement, the Executive may locate, identify and/or evaluate patented or
patentable inventions having commercial potential in the fields of pharmacy, pharmaceutical, biotechnology, healthcare, technology and other fields which may be of potential interest to the Company or one of its affiliates (the “Third Party
Inventions”). The Executive understands, acknowledges and agrees that all rights to, interests in or opportunities regarding, all Third-Party Inventions identified by the Company, any of its affiliates or either of the foregoing
persons’ officers, directors, employees (including the Executive), agents or consultants during the Employment Term shall be and remain the sole and exclusive property of the Company or such affiliate and the Executive shall have no rights
whatsoever to such Third-Party Inventions and will not pursue for himself or for others any transaction relating to the Third-Party Inventions which is not on behalf of the Company. 
 (e) The provisions of this Section 6 shall survive any termination of this Agreement. 
 7. Non-Competition, Non-Solicitation and Non-Disparagegment. 
 (a) While Executive is employed by the Company and for a period of twelve (12) months after the termination or cessation of such employment by either party for any reason whatsoever, Executive will not, directly
on his own behalf or indirectly for or in conjunction with others: 
 (i) Within the Restricted Territory (as defined in subsection
(b) below), engage in any business or enterprise (whether as owner, partner, officer, director, employee, consultant, investor, lender or otherwise) in competition with the Company, where such business or enterprise develops, manufactures,
markets, licenses or sells any products designed to treat immunological diseases, including but not limited to rheumatoid arthritis (“RA”), cancer, psoriasis, and other anti-inflammatory conditions or any other conditions including but not
limited to neurogenic orthostatic hypotension, intradialytic hypotension and fibromyalgia that compete with the products being sold or developed by the Company at the time of Executive’s termination (collectively, the “Competitive
Products”) in any management or executive role or in any position (whether as an employee, contractor or consultant) in which Executive or a third party would benefit from Executive’s use or disclosure of the Company’s Confidential
Information; 







 (ii) Within the Restricted Territory, solicit or accept employment or be retained by an individual or
entity who, at any time during the term of this Agreement, was an agent, client, licensee, or customer of the Company, where the Executive would have any management or executive role or be in any position (whether as an employee, contractor or
consultant) in which the Executive or a third party would benefit from Executive’s use or disclosure of the Company’s Confidential Information; 
 (iii) Within the Restricted Territory, become financially interested in an enterprise that is engaged, as a substantial part of its operations, in selling the Competitive Products; provided, however, that
nothing in this Agreement shall be construed to prevent Executive from owning less than five percent (5%) of the outstanding voting securities of any entity whose voting securities are listed on a national securities exchange or quoted by the
NASDAQ automated quotation system; 
 (iv) Solicit or accept the business of any customer of the Company whom Executive solicited or
serviced for the Company during the last twelve (12) months of Executive’s employment with the Company; and/or 
 (v) Solicit or
induce any employee, consultant, or independent contractor of the Company to terminate the employment or contracting relationship with the Company. 
 (b) For purposes of this Agreement, the “Restricted Territory” means the United States of America and Canada. 
 (c) During the Term of this Agreement and at all times thereafter, the Company and Executive each further agree that neither party shall directly or indirectly disparage the name or reputation of the other party or any of its affiliates,
including but not limited to, any officer, director, employee or shareholder of the Company or any of its affiliates. 
 (d) If Executive
breaches any provisions of this Agreement or there is a threatened breach, then, in addition to any other rights which the Company may have, the Company shall (i) be entitled to injunctive relief to enforce these restrictions and (ii) have
the right to require Executive to account for and pay over to the Company all compensation, profits, monies, accruals, increments and other benefits (collectively, the “Benefits”) derived or received by Executive as a result of any
transaction constituting a breach of any of the provisions of Section 7 and Executive hereby agrees to account for and pay over such Benefits to the Company. 
 (e) Each of the rights and remedies enumerated in Section 7(d) shall be independent of the others and shall be in addition to, and not in lieu of, any other rights and remedies available to the Company at law or
in equity. If any of the covenants contained in this Section 7, or any part of any of them, is hereafter construed or adjudicated to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants or rights or
remedies which shall be given full effect without regard to the invalid portions. If any of the covenants contained in this Section 7 is held to be invalid or unenforceable because of the duration of such provision or the area covered thereby,
the parties agree that the court making such determination shall have the power to reduce the duration and/or area 








 
of such provision and in its reduced form such provision shall then be enforceable. No such holding of invalidity or unenforceability in one jurisdiction
shall bar or in any way affect the Company’s right to the relief provided in this Section 7 or otherwise in the courts of any other state or jurisdiction within the geographical scope of such covenants as to breaches of such covenants in
such other respective states or jurisdictions, such covenants being, for this purpose, severable into diverse and independent covenants. 
 (f) The provisions of this Section 7 shall survive any termination of this Agreement. 
 8. Representations and Warranties
by the Executive. 
 The Executive hereby represents and warrants to the Company as follows: 
 (a) Neither the execution or delivery of this Agreement nor the performance by the Executive of his duties and other obligations hereunder violate or will
violate any statute, law, determination or award, or conflict with or constitute a default or breach of any covenant or obligation under (whether immediately, upon the giving of notice or lapse of time or both) any prior employment agreement,
contract, or other instrument to which the Executive is a party or by which he is bound. 
 (b) The Executive has the full right, power and
legal capacity to enter and deliver this Agreement and to perform his duties and other obligations hereunder. This Agreement constitutes the legal, valid and binding obligation of the Executive enforceable against him in accordance with its terms.
No approvals or consents of any persons or entities are required for the Executive to execute and deliver this Agreement or perform his duties and other obligations hereunder. 
 9. Termination. The Executive’s employment hereunder shall terminate immediately upon the Executive’s death. In addition, this Agreement
may be terminated as follows: 
 (a) The Executive’s employment hereunder may be terminated by the Board for Cause.
“Cause” shall be determined by a majority of the Board (excluding Executive) and shall mean: 
 (i) The willful failure,
disregard or refusal by the Executive to perform his duties hereunder; 
 (ii) Any willful, intentional or grossly negligent act by the
Executive having the effect of injuring, in a material way (whether financial or otherwise), the business or reputation of the Company or any of its affiliates, including but not limited to, any officer, director, executive or shareholder of the
Company or any of its affiliates. 
 (iii) Willful misconduct by the Executive in respect of the duties or obligations of the Executive
under this Agreement, including, without limitation, insubordination with respect to lawful directions received by the Executive from the Board; 







 (iv) The Executive’s conviction of any felony (including entry of a nolo contendere or no contest
plea); 
 (v) The determination by the Company, after a reasonable and good-faith investigation by the Company following a written
allegation by another employee of the Company, that the Executive engaged in some form of harassment prohibited by law (including, without limitation, discrimination based on race, color, religion, sex, national origin, age, disability or other
status protected by law), unless the Executive’s actions were specifically directed by the Board; 
 (vi) Any misappropriation or
embezzlement of the property of the Company or its affiliates (whether or not a misdemeanor or felony); 
 (vii) Breach by the Executive of
any of the provisions of Sections 6, 7 or 8 of this Agreement; and 
 (viii) Breach by the Executive of any provision of this Agreement
other than those contained in Sections 6, 7 or 8 that, if capable of being cured, is not cured by the Executive within thirty (30) days after notice thereof is given to the Executive by the Company. 
 (b) The Executive’s employment hereunder may be terminated by the Board due to the Executive’s Disability. For purposes of this Agreement, a
termination for “Disability” shall occur (i) when the Board has provided a written termination notice to the Executive supported by a written statement from a reputable independent physician to the effect that the Executive
shall have become so physically or mentally incapacitated as to be unable to resume, within the ensuing twelve (12) months, his employment hereunder by reason of physical or mental illness or injury with or without a reasonable accomodation, or
(ii) upon rendering of a written termination notice by the Board after the Executive has been unable to substantially perform his duties hereunder for 90 or more consecutive days, or more than 120 days in any consecutive twelve month period, by
reason of any physical or mental illness or injury with or without a reasonable accomodation. For purposes of this Section 9(b), the Executive agrees to make himself available and to cooperate in any reasonable examination by a reputable
independent physician retained by the Company. 
 (c) The Executive’s employment hereunder may be terminated by the Executive for Good
Reason. For purposes of this Agreement, “Good Reason” shall mean any of the following: (i) the assignment to the Executive of duties materially inconsistent with the Executive’s position, duties, responsibilities, titles
or offices as described herein; (ii) any material reduction by the Corporation of the Executive’s duties and responsibilities; (iii) any material reduction by the Corporation of the Executive’s compensation or benefits payable
hereunder (it being understood that a reduction of benefits applicable to all employees of the Corporation, including the Executive, shall not be deemed a reduction of the Executive’s compensation package for purposes of this definition); or
(vi) the occurrence of a Change of Control of the Company. For purposes of this Agreement, “Change of Control” means (i) the acquisition, directly or indirectly, following the date hereof, by any person (as such term is
defined in Section 3(a)(9) and as modified and used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended), of securities of the Company resulting in such 








 
person owning, after such acquisition, in excess of fifty percent (50%) of the combined voting power of the Company’s then outstanding securities,
(ii) the disposition by the Company (whether direct or indirect, by sale of assets or stock, merger, consolidation or otherwise) of all or substantially all of its business and/or assets in one transaction or series of related transactions
(other than a merger effected exclusively for the purpose of changing the domicile of the Company or otherwise unrelated to a change of majority ownership or control of the Company or the business and/or assets of the Company involved in such
transaction) or (iii) the individuals who on the date of this Agreement constitute the Board and any subsequent Board-approved directors cease for any reason to constitute a majority of the Board (for this purpose a “Board-approved
director” is any director duely elected or appointed according to the Company’s bylaws after the date of this Agreement and whose nomination, election or appointment was approved by a vote of the directors then in office who either were
directors of the Company on the date of this Agreement or whose election or appointment was previously so approved). 
 10. Compensation
upon Termination. 
 (a) If the Executive’s employment terminates as a result of his death or Disability, the Company shall pay to
the Executive or to the Executive’s estate, as applicable, his Base Salary for a period of one (1) year following the date of termination and any earned but unpaid Incentive Bonus, plus any unpaid reimbursement amounts for business
expenses, medical licensing fees, or professional dues incurred through the date of his Death or Disability. The Company shall pay the Base Salary in equal bi-monthly installments, beginning within fifteen (15) days immediately following his
termination. The Company shall pay any other amounts due pursuant to this paragraph at the same time the amount would have been paid had the Executive remained employed by the Company. Payments to be made under this paragraph are hereby designated
and shall at all times be treated as a series of separate payments and not a single payment pursuant to Treasury Regulation § 1.409A-2(b)(2)(iii). Except as provided under the terms of the Company’s employee benefit plans (as generally
applied to executive officers, the Executive shall have no further entitlement to any other compensation or benefits from the Company. 
 (b)
If the Executive’s employment is terminated by the Board for Cause, then the Company shall pay to the Executive his Base Salary through the date of his termination and any expense reimbursement amounts owed through the date of termination.
Except as provided under the terms of the Company’s employee benefit plans (as generally applied to executive officers ), the Executive shall have no further entitlement to any other compensation or benefits from the Company. 
 (c) If the Executive’s employment is terminated by the Company (or its successor) other than for Cause (and not due to Executive’s death or
Disability) or by the Executive for Good Reason, then subject to Executive executing (and not revoking) a general release of any employment-related claims in the Company’s favor within sixty (60) days of the termination date: 

(i) Until the end of the Term or for a period of one year following such termination, whichever is longer, the Company (or its successor, as
applicable) shall 







 (1) Continue to pay to the Executive an amount equal to his Base Salary and any earned
but unpaid Incentive Bonus, plus any unpaid reimbursement amounts for business expenses, medical licensing fees, or professional dues incurred through the date of termination; and 
 (2) Pay to the Executive an amount equal to COBRA premiums that would be paid by the Executive each month for continuation coverage for
Executive and his spouse and dependents, but only to the extent such COBRA premiums exceed the premiums or contributions the Executive would have paid for such coverage as an active employee of the Company. 
 The Company shall pay the Base Salary in equal bi-monthly installments, beginning within fifteen (15) days
immediately following his termination. Notwithstanding the foregoing, any amount that would be payable within the 60-day period following executive’s termination if Executive signed and did not revoke the general release on the day of his
termination shall be delayed until the 61st day following Executive’s termination. The Company shall pay the COBRA payment on the first day of
the month immediately following the month to which it relates. Each such COBRA payment shall be treated as taxable wages to the Executive. The Company shall pay any other amounts due pursuant to this paragraph at the same time the amount would have
been paid had the Executive remained employed by the Company; 
 (ii) On the termination date, 
 (1) All of Executive’s stock options, stock awards, and other grants of equity compensation shall be accelerated and deemed to have
vested as of the termination date (without regard to any installment exercise limitations set forth in the applicable award or grant agreements); and 
 (2) All of Executive’s stock options, stock awards, and other grants of equity compensation that are awarded during the Term and that are subject to exercise shall remain exercisable until the earlier of
(x) 180 days following Executive’s termination, or (y) the latest date upon which the award or grant could have expired by its original terms if the Executive had remained employed; and 
 (iii) Except as provided under the terms of the Company’s employee benefit plans (including but not limited to 401(k), group insurance and equity
compensation plans), the Executive shall have no further entitlement to any other compensation or benefits from the Company. 
 (d)
Notwithstanding paragraph (c) above, and unless otherwise agreed by the Company and the Executive, if the Executive’s employment is terminated by the Company (or its successor) within 90 days of the occurrence of a Change of Control and on
the date of the Change of Control the fair market value of the Company’s Common Stock, in the aggregate, as reported by NASDAQ Capital Markets or otherwise as determined in good faith by the Board on the date of such Change of Control, is less
than $50,000,000, then the Company (or its successor, as applicable) shall continue to pay to the Executive an amount equal to his Base Salary, plus any 








 
unpaid reimbursement amounts for business expenses, medical licensing fees, or professional dues incurred through the date of termination and shall pay to
the Executive an amount equal to COBRA premiums that would be paid by the Executive each month for continuation coverage for Executive and his spouse and dependents, but only to the extent such COBRA premiums exceed the premiums or contributions the
Executive would have paid for such coverage as an active employee of the Company, until the end of the term or for a period of one year following such termination, whichever is shorter, as well as any expense reimbursement amounts owed through the
date of termination. All Stock Options shall be accelerated and deemed to have vested as of the termination date. Except as provided under the terms of the Company’s employee benefit plans (as generally applied to executive officers ), the
Executive shall have no further entitlement to any other compensation or benefits from the Company. 
 (e) Except as provided under the terms
of the Company’s employee benefit plans (as generally applied to executive officers), this Section 10 sets forth the only obligations of the Company with respect to the termination of the Executive’s employment with the Company, and
the Executive acknowledges that, upon the termination of his employment, he shall not be entitled to any payments or benefits which are not explicitly provided in Section 10 or under the terms of the Company’s employee benefit plans.

 (f) Following expiration and non-renewal of the Term, should the Company, in its sole discretion require that the Executive continue to
comply with the terms of Section 7 hereof following termination of Executive’s employment, the Company shall pay the Executive his Base Salary for a period of one year. The Company shall pay the Base Salary in equal bi-monthly
installments, beginning within fifteen (15) days immediately following his termination. The Company (or its successor, as applicable) shall pay any other amounts due pursuant to this paragraph at the same time the amount would have been paid
had the Executive remained employed by the Company. In the event of the termination of Executive’s employment pursuant to Section 10(b) or 10(c) hereof, then Executive shall continue to comply with the terms of Section 7 hereof
without any additional consideration paid by the Company. 
 (g) Upon termination of the Executive’s employment hereunder for any
reason, the Executive shall be deemed to have resigned as director of the Company, effective as of the date of such termination. 
 (h)
Payments to be made under this Section 10 are hereby designated and shall at all times be treated as a series of separate payments and not a single payment pursuant to Treasury Regulation § 1.409A-2(b)(2)(iii). To the maximum extent
permitted under Section 409A, the payments described in this Section 10 are intended to qualify as short-term deferrals meeting the requirements of Treas. Reg. § 1.409A-1(b)(9)(iii). 
 (i) To the extent applicable, the parties hereto intend that this Agreement comply with Section 409A of the Code and all guidance or regulations
thereunder (“Section 409A”), including without limitation compliance with all applicable exemptions from Section 409A (e.g., the short-term deferral exception). The parties hereby agree that this Agreement shall at all times be
construed in a manner to comply with Section 409A and that should any provision be found not in compliance with Section 409A, the parties are hereby contractually obligated to execute any and all amendments to this Agreement deemed
necessary and required 








 
by legal counsel for the Company to achieve compliance with Section 409A. In the event amendments are required to be made to this Agreement to comply
with Section 409A, the Company shall use its commercially reasonable best efforts to provide the Executive with substantially the same benefits and payments he would have been entitled to pursuant to this Agreement had Section 409A not
applied, but in a manner that is compliant with Section 409A. The manner in which the immediately preceding sentence shall be implemented shall be the subject of good faith negotiations of the parties. The parties also agree that in no event
shall any payment required to be made pursuant to this Agreement that is considered deferred compensation within the meaning of Section 409A be accelerated or deferred in violation of Section 409A. The parties further agree that any
payments of deferred compensation that are to be made as a result of the Executive’s separation from service must be delayed pursuant to Section 409A until the earlier of the day that is six (6) months plus one day after such
separation from service, or death of the Executive, but only if the Executive is determined to be a “specified employee” (as that term is defined in Section 409A) and only to the extent the delay is required under Section 409A.

 (j) If Executive dies prior to receiving any or all of the payments, monthly installments or benefits to which he is due under this
Section 10, then such remaining payments, monthly installments or benefits shall be payable to his estate with no change in the time or form of payment. 
 (k) The provisions of this Section 10 shall survive any termination of this Agreement. 
 11.
Miscellaneous. 
 (a) This Agreement is governed by and will be construed and interpreted in accordance with the laws of the State of
North Carolina, without reference to its conflict of laws principles. 
 (b) Any dispute arising out of, or relating to, this Agreement or
the breach thereof, or regarding the interpretation thereof (except for any disputes arising out of or related to Sections 6 or 7 of the Agreement), shall be finally settled by binding arbitration conducted in Charlotte, North Carolina and
administered by the American Arbitration Association (“AAA”) pursuant to its then-current Employment Arbitration Rules and Mediation Procedures (available at www.adr.org). The arbitration shall be conducted by a single experienced
arbitrator or retired judge, to be chosen via the AAA’s selection procedures. The arbitrator’s award shall be final and binding. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.
The arbitrator may award monetary damages and, in the arbitrator’s discretion, attorneys’ fees and/or costs to the prevailing party if allowed by statute. The arbitrator may not award punitive damages or any other type of exemplary damages
unless such damages are specifically authorized by statute. Any filing fees and the fees and costs of the arbitrator shall be paid equally by the Company and Executive. Each party shall pay the fees of his or her attorneys, the expenses of his or
her witnesses, and any other expenses that party incurs in connection with the arbitration. For the purpose of any judicial proceeding to enforce such award or incidental to such arbitration or to compel arbitration and for purposes of Sections 6
and 7 hereof, the parties hereby submit to the sole and exclusive jurisdiction of the state or 








 
federal courts sitting in Mecklenburg County, North Carolina, and agree that service of process in such arbitration or court proceedings shall be
satisfactorily made upon it or him if sent by registered mail addressed to it or him at the address referred to in Section 11(g) of this Agreement. 
 (c) This Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective heirs, legal representatives, successors and assigns. 
 (d) This Agreement, and the Executive’s rights and obligations hereunder, may not be assigned by the Executive. The Company may assign its rights,
together with its obligations, hereunder in connection with any sale, transfer or other disposition of all or substantially all of its business or assets. 
 (e) This Agreement cannot be amended orally, or by any course of conduct or dealing, but only by a written agreement signed by the parties hereto. 
 (f) The failure of either party to insist upon the strict performance of any of the terms, conditions and provisions of this Agreement shall not be
construed as a waiver or relinquishment of future compliance therewith, and such terms, conditions and provisions shall remain in full force and effect. No waiver of any term or condition of this Agreement on the part of either party shall be
effective for any purpose whatsoever unless such waiver is in writing and signed by such party. 
 (g) All notices, requests, consents and
other communications, required or permitted to be given hereunder, shall be in writing and shall be delivered personally or by an overnight courier service or sent by registered or certified mail, postage prepaid, return receipt requested, to the
parties at the addresses set forth on the first page of this Agreement, and shall be deemed given when so delivered personally or by overnight courier, or, if mailed, five days after the date of deposit in the United States mail. Either party may
designate another address, for receipt of notices hereunder by giving notice to the other party in accordance with this paragraph (g). 
 (h)
This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter hereof, and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter hereof. No
representation, promise or inducement has been made by either party that is not embodied in this Agreement, and neither party shall be bound by or liable for any alleged representation, promise or inducement not so set forth. 
 (i) As used in this Agreement, “affiliate” of a specified Person shall mean and include any Person controlling, controlled by or under
common control with the specified Person. 
 (j) The section headings contained herein are for reference purposes only and shall not in any
way affect the meaning or interpretation of this Agreement. 







 (k) This Agreement may be executed in any number of counterparts, each of which shall constitute an
original, but all of which together shall constitute one and the same instrument. 
 [Remainder of Page Intentionally Left Blank]








 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

  

			
	CHELSEA THERAPEUTICS INTERNATIONAL, LTD.
		
	By:	 	 /s/ J. Nick Riehle

	Name:	 	J. Nick Riehle
	Title:	 	Chief Financial Officer
	
	EXECUTIVE
		
	By:	 	 /s/ Simon Pedder

	Name:	 	Dr. Simon Pedder